Neurality secures $12M to develop gut-brain axis EEG biomarker companion diagnostic
Summary
Maryland-based Neurality raised $12M Series A extension from Pfizer Ventures and Atlas Venture to develop an EEG-based companion diagnostic for their NAL-101 GABA modulator, measuring enteric nervous system-cortical connectivity biomarkers that predict drug response. The diagnostic would be co-developed with NAL-101 as an integrated precision psychiatry package.
Why it matters
A companion diagnostic developed alongside a lead drug candidate creates a precision psychiatry package with strong regulatory and commercial advantages. FDA has been receptive to companion diagnostic co-development for psychiatric drugs, and this approach mirrors Alto Neuroscience's successful EEG biomarker strategy.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial